



Identification of benzofuran-4,5-diones as novel and selective non-hydroxamic acid, non-peptidomimetic based inhibitors of human peptide deformylase

Christophe Antczak^a, David Shum^a, Bhramdeo Bassit^a, Mark G. Frattini^b, Yueming Li^a, Elisa de Stanchina^a, David A. Scheinberg^a, Hakim Djaballah^{a,*}

^a Department of Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA

^b Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA

ARTICLE INFO

Article history:

Received 18 April 2011

Revised 27 May 2011

Accepted 31 May 2011

Available online 12 June 2011

Keywords:

Human peptide deformylase

Benzofuran-4,5-diones

Structure–activity relationships

Fluorescence polarization

Antiproliferative agents

ABSTRACT

Selective inhibitors of human peptide deformylase (HsPDF) are predicted to constitute a new class of antitumor agents. We report the identification of benzofuran-4,5-diones as the first known selective HsPDF inhibitors and we describe their selectivity profile in a panel of metalloproteases. We characterize their structure–activity relationships for antitumor activity in a panel of cancer cell lines, and we assess their *in vivo* efficacy in a mouse xenograft model. Our results demonstrate that selective HsPDF inhibitors based on the benzofuran-4,5-dione scaffold constitute a novel class of antitumor agents that are potent *in vitro* and *in vivo*.

© 2011 Elsevier Ltd. All rights reserved.

During protein synthesis in prokaryotes, the N-formyl group of nascent peptides is removed from most peptides in order to yield mature proteins. Consequently, PDF activity is essential to bacterial growth.^{1,2} Since until recently PDF was thought to be absent from eukaryotes, PDF has constituted an attractive target for the development of antibiotics.³ However, the demonstration of the existence of a functional human analogue of PDF^{4–6} raises concerns over the use of non selective PDF inhibitors as antibacterial agents in humans.

Following the observation that HsPDF inhibition by actinonin (**1**) and actinonin analogs or by specific siRNA knockdown of expression is associated with antiproliferative effect in cancer cells⁷, we speculated that HsPDF inhibitors could constitute a new class of antitumor agents. However, most currently known PDF inhibitors such as actinonin consist of a peptidomimetic backbone attached to a hydroxamic acid moiety, and this class of compounds is typically associated with poor selectivity across metalloproteases.^{8–11} In addition, their poor bioavailability precludes their use *in vivo* as antitumor agents. The crystal structure of an N-terminal truncated, catalytically active HsPDF revealed structural differences between HsPDF and EcPDF such as a characteristic entrance to the active site that provide a rationale for the identification of selective HsPDF inhibitors.¹² For

this reason, we developed and validated a strategy that would allow us to identify novel non peptidomimetic and non hydroxamic acid based inhibitors of HsPDF¹³, and we subsequently embarked on the screening of a library of 200,000 small molecules using our proven strategy. Among the confirmed positives identified in this campaign were five compounds (**2–6**) belonging to the chemical scaffold of benzofuran-4,5-diones (Fig. 1). All five compounds induced $\geq 75\%$ inhibition at 10 μM in our fluorescence polarization-based assay for HsPDF (Fig. 1) in absence of any optical interference, which was measured as previously described.¹³ In addition, the five benzofuran-4,5-diones identified during primary screening were confirmed as functional inhibitors of HsPDF using a methodology previously described.¹³ While the benzofuran moiety is included in inhibitors of various enzymes, to our knowledge, no inhibitory activity toward any PDF and no antitumor activity has previously been described for the chemical scaffold of benzofuran-4,5-diones. In order to expand the limited structure–activity relationships of benzofuran-4,5-diones gathered during primary screening, we initiated exploratory chemistry efforts aimed at defining the importance of the halogen substitutions at α - and β -positions on the 4,5-orthodione moiety.

For the synthesis of 13 novel benzofuran-4,5-dione derivatives and three naphthofurandione derivatives, we engaged in a strategy relying on acid catalyzed reaction of substituted enaminones with appropriately halogenated 1,4-quinones^{14–17} to provide a general

* Corresponding author. Tel.: +646 888 2198; fax: +646 422 0706.

E-mail address: djaballah@mskcc.org (H. Djaballah).





Figure 1. Chemical structure of actinonin, **1**; chemical structure and percentage inhibition (HTS%) of confirmed positives in primary screen belonging to the benzofuran-4,5-dione scaffold, **2–6**; general chemical structure of the primary hits belonging to the benzofuran-4,5-dione scaffold.


construct of substituted 5-hydroxy benzofuran and naphthofuran derivatives, followed by oxidation with a suitable oxidant. Toward this end, substituted acetophenones **7a–7d** were reacted with dimethyl formamide dimethyl acetal at 150 °C in DMF to give the enaminones **8a–8d**¹⁸ in 63–88% yield (Scheme 1). The enaminones **8a–8d** were reacted with appropriately halogenated 1,4-quinones




Scheme 1. Synthesis of the enaminones **8a–8d**. Reagents and conditions: (a) DMF-DMA, 150 °C, 20–30 h.

and hydroquinone in acetic acid as a solvent to give the corresponding 5-hydroxybenzofuran derivatives **16i–30i**^{19,20} (Scheme 2), as well as the corresponding 5-hydroxynaphthofuran derivatives **32i–34i**²¹ (Scheme 3) in variable yields. The oxidation of 5-hydroxybenzofuran derivatives **16i–28i** and 5-hydroxynaphthofuran derivatives **32i–34i** was best accomplished via either nitric acid^{22,23} or with Dess–Martin's periodinane, to give the corresponding substituted 4,5-benzofurandiones **16–28** with 40–57% yield and the 4,5-naphthofurandiones **32–34** with 38 to 43% yield.

We evaluated the potency of the 13 novel benzofuran-4,5-dione derivatives toward HsPDF and EcPDF as well as their selectivity profile using a previously validated methodology.¹⁰ We found that all the benzofuran-4,5-dione derivatives we have synthesized inhibit HsPDF with an IC₅₀ ranging from 5.2 to 65 μM (Table 1). In contrast, when we characterized the potency of the 5-hydroxybenzofuran intermediates of synthesis **16i–30i**, we found that they were all inactive toward HsPDF up to 100 μM (Supplementary Table 1). This result clearly indicates that the orthodione moiety in the benzofuran-4,5-dione scaffold is important for activity. Similarly, the three naphthofurandiones **32**, **33** and **34** we have synthesized have no activity toward any of the metalloproteases tested (Supplementary Table 2), suggesting that substituting the benzofurandione moiety by a naphthofurandione moiety abrogates activity. Interestingly, since the benzofurandiones **16** and **17** lacking a halogen substituent at α- and β-positions on the 4,5-orthodione moiety are potent toward HsPDF (Table 1), we can conclude that




Scheme 2. Synthesis of benzofuran-4,5-diones. Reagents and conditions: (a) AcOH, rt; (b) For **16**, **17**, **19**, **21**, **28**: Dess–Martin periodinane, DMSO, 0 °C–rt, 20 min; For **5**, **20**, **22–27**: HNO₃, AcOH, rt→65 °C, 3 h. Z = Br or Cl, matching X and Y.



Scheme 3. Synthesis of naphthofurandiones. Reagents and conditions: (a) AcOH, rt; (b) HNO₃, AcOH, rt→50 °C, 30 min.

Table 1
Potency and selectivity profile of benzofuran-4,5-dione derivatives



Compd	X	Y	R ¹	R ²	R ³	HsPDF (IC ₅₀ , μM)	EcPDF (IC ₅₀ , μM)	HsPDF (%)	EcPDF (%)	APN (%)	MMP-1 (%)
1	—	—	—	—	—	2.7	0.14*	98	99	95	97
16	H	H	H	H	H	59	>100	100	32	5	0
17	H	H	H	OMe	H	34	>100	100	24	4	6
20	Cl	H	H	OMe	H	40	>100	100	11	54	11
28	Br	H	H	OMe	H	32	>100	100	5	22	26
19	H	Cl	H	OMe	H	16	>100	100	13	68	10
21	H	Br	H	OMe	H	15	>100	100	26	64	8
5	Cl	Cl	H	H	H	45	>100	100	65	101	41
22	Cl	Cl	H	OMe	H	15	>100	88	1	50	0
25	Br	Br	H	OMe	H	65	>100	100	22	41	23
23	Cl	Cl	OMe	OMe	H	6.1	67	100	63	99	46
26	Br	Br	OMe	OMe	H	10	>100	100	53	96	46
24	Cl	Cl	OMe	OMe	OMe	25	>100	100	27	50	32
27	Br	Br	OMe	OMe	OMe	5.2	>100	100	32	50	38

%I: % Inhibition at 100 μM, average of duplicates; 100: ≥100 %I; 0: ≤0 %I.
* as assessed in the FLUO functional assay¹³.




Figure 2. (a) Dose response curves for **22** and **27** toward HsPDF and EcPDF. (b) Cytotoxicity profiling of **27**.

halogens in those positions are not required for activity, and that the naphthofurandiones **32**, **33** and **34** are not inactive because they




Figure 3. In vivo efficacy of **27** in a mouse xenograft model using HL-60 cells.

lack halogens, but rather because the benzofuran-4,5-dione moiety is necessary for activity. While halogen substitutions at α - and β -positions on the 4,5-orthodione moiety are not required for HsPDF activity, they do seem to increase the potency of benzofuran-4,5-diones toward HsPDF, since the top six most potent derivatives we have synthesized harbor at least one chloro or one bromo substituent in those positions. Similarly, we observe that the top three most potent derivatives have two or three methoxy substituents on the benzoyl moiety (Table 1), indicating that those substituents could be responsible for the formation of hydrogen bonds with the target. With an IC₅₀ of 5.2 μM toward HsPDF, **27** is the most potent HsPDF inhibitor we have characterized. When we assessed the selectivity of benzofuran-4,5-diones, we found that only one of the derivatives we have synthesized was weakly active toward EcPDF (**23**, IC₅₀ = 67 μM), while 12 out of 13 had no measurable activity toward EcPDF (Table 1). This result contrasts with the broad activity of benzofuran-4,5-diones toward the human enzyme and demonstrates that this class of compounds is selective for the human PDF compared to the bacterial enzyme.

Table 2
Cytotoxicity profile of benzofuran-4,5-dione derivatives

Compd	HL-60	HL-60/RV+	Jurkat	Molt-3	ALL-3	CWR22	HEK293	Y79	Meso47
1	16	100	40	45	N.D.	25	15	N.D.	100
16	21	22	8.1	7.3	22	30	23	30	63
17	17	27	8.9	9.1	29	35	21	31	100
20	32	67	57	47	34	69	100	67	71
28	48	67	20	4	48	71	54	100	71
19	17	48	13	11	47	59	40	74	100
21	10	38	12	11	35	46	36	63	100
5	72	100	46	31	69	72	100	100	100
22	10	43	6.1	4.1	27	50	30	66	100
25	53	100	55	40	70	70	100	68	100
23	69	100	67	71	69	68	100	66	72
26	42	64	28	25	36	100	100	100	100
24	36	55	5.9	7.0	49	67	67	64	100
27	5.4	12	2.8	2.9	10	21	16	33	37

IC₅₀, μM ; 100: ≥ 100 μM; N.D.: not determined.

To our knowledge, benzofuran-4,5-diones constitute the first class of compounds with such a specificity, since all currently known HsPDF inhibitors are peptidomimetic- and hydroxamic acid-based that inhibit both HsPDF and EcPDF^{6,8,24}, and tend to exhibit low specificity among metalloproteases.^{8–11} When we further characterized the selectivity profile of benzofuran-4,5-diones at 100 μM in a panel of metalloproteases, we found that the newly synthesized compounds are not only selective for HsPDF compared to EcPDF, but also demonstrate selectivity for HsPDF among other metalloproteases such as APN and MMP-1; as an example, **22** had no significant activity toward EcPDF and MMP-1, while being potent toward HsPDF (IC₅₀ = 15 μM) (Table 1, Fig. 2a). Similarly, **16**, **17** and **28** completely inhibited HsPDF while having low activity toward EcPDF, APN and MMP-1 (Table 1). Altogether, our results demonstrate that benzofuran-4,5-diones constitute the first known selective inhibitors of HsPDF. With an IC₅₀ of 5.2 μM toward HsPDF and no significant activity toward the bacterial enzyme (Table 1, Fig. 2a), **27** is the most potent and selective HsPDF inhibitor we have characterized.

To confirm that the novel HsPDF inhibitors we have identified have no antibacterial activity as predicted by their lack of activity toward EcPDF, we determined the MIC of compounds **5** and **22** in a panel of 15 bacterial strains. We found that none of the compounds had measurable antibacterial activity toward 14 out of the 15 strains tested (MIC >64 μg/mL), while actinonin was active in 12 out of the 15 strains tested as expected (Supplementary Table 3). This important result confirms that benzofuran-4,5-diones constitute the first known HsPDF inhibitors that specifically target the human enzyme and lack antibacterial activity, presumably because they are structurally different than actinonin and its derivatives and do not contain a hydroxamic acid moiety.

To verify the hypothesis that HsPDF inhibitors may constitute novel anticancer agents, we assessed the cytotoxicity profile of the 13 novel benzofuran-4,5-dione derivatives in a panel of nine well characterized cancer cell lines using a method previously described.²⁵ We found that all the benzofuran-4,5-dione derivatives we have synthesized have cytotoxic activity toward at least five out of nine of the cancer cell lines tested, with an IC₅₀ ranging from 2.8 to 74 μM (Table 2). Interestingly, the most potent HsPDF inhibitor we have identified was also the most potent compound in the viability assay: **27** was active across all the cancer cell lines tested, with IC₅₀ ranging from 2.8 to 37 μM, including the multidrug resistant cell line HL-60/RV+ (IC₅₀ = 12 μM) (Table 2, Fig. 2).

In summary, our findings provide guidelines for the development of selective HsPDF inhibitors active at the cellular level and altogether our results validate our strategy, in that we have de-

signed novel and selective HsPDF inhibitors that have cell-based anticancer activity.

In a pilot study, we assessed the in vivo efficacy of **27** in a mouse xenograft model using human promyelocytic leukemia HL-60 cells. Our lead compound delayed the growth of HL-60 tumors by up to 40% (Fig. 3). To put this result in perspective, actinonin – which has a reported IC₅₀ of 43 nM toward HsPDF⁷—must be administered twice a day for two weeks at the large dose of 250 mg/kg to delay tumor growth.⁷ This difference in potency could be attributed to a better bioavailability compared to the peptidomimetic actinonin but further studies are needed to address this question. In light of this observation, our results are encouraging considering that **27**, a benzofuran-4,5-dione derivative of first generation, was potent in vivo at a dose of 15 mg/kg.

In conclusion, our findings strongly suggest that derivatives of the benzofuran-4,5-dione scaffold could constitute a new class of potent antitumor agents selective for HsPDF.

Acknowledgments

The authors thank Constantin Radu and the other members of the High Throughput Screening Core Facility for their help during the course of this study. The authors are grateful to Kumaraswamy Sorra, Benarjee Velaga, Srinivas Oruganti and Narinder Mohal for the chemical synthesis of the new derivatives described in this study. The HTS Core Facility is partially supported by Mr. William H. Goodwin and Mrs. Alice Goodwin and the Commonwealth Foundation for Cancer Research, the Experimental Therapeutics Center of MSKCC, the William Randolph Hearst Fund in Experimental Therapeutics, the Lilian S Wells Foundation and by an NIH/NCI Cancer Center Support Grant 5 P30 CA008748-44. This study was funded by NIH grant 1R21NS57008 (HD).

Supplementary data

Supplementary data (supplementary tables, experimental procedures, spectroscopic data and NMR data for all compounds) associated with this article can be found, in the online version, at doi:10.1016/j.bmcl.2011.05.129.

References and notes

- Mazel, D.; Pochet, S.; Marliere, P. *EMBO J.* **1994**, *13*, 914.
- Meinzel, T.; Blanquet, S. *J. Bacteriol.* **1994**, *176*, 7387.
- Meinzel, T.; Patiny, L.; Ragusa, S.; Blanquet, S. *Biochemistry* **1999**, *38*, 4287.
- Serero, A.; Giglione, C.; Sardini, A.; Martinez-Sanz, J.; Meinzel, T. *J. Biol. Chem.* **2003**, *278*, 52953.

5. Lee, M. D.; Antczak, C.; Li, Y.; Sirotnak, F. M.; Bornmann, W. G., et al *Biochem. Biophys. Res. Commun.* **2003**, *312*, 309.
6. Leeds, J. A.; Dean, C. R. *Curr. Opin. Pharmacol.* **2006**, *6*, 445.
7. Lee, M. D.; She, Y.; Soskis, M. J.; Borella, C. P.; Gardner, J. R.; Hayes, P. A.; Dy, B. M.; Heaney, M. L.; Philips, M. R.; Bornmann, W. G.; Sirotnak, F. M.; Scheinberg, D. A. *J. Clin. Invest.* **2004**, *114*, 1107.
8. Kontogiorgis, C.; Papaioannou, P.; Hadjipavlou-Litina, D. *Curr. Med. Chem.* **2005**, *12*, 339.
9. Saghatelian, A.; Jessani, N.; Joseph, A.; Humphrey, M.; Cravatt, B. *Proc. Natl. Acad. Sci. U.S.A.* **2004**, *101*, 10000.
10. Antczak, C.; Radu, C.; Djaballah, H. *J. Biomol. Screen* **2008**, *13*, 285.
11. Overall, C.; Kleinfeld, O. *Nat. Rev. Cancer* **2006**, *6*, 227.
12. Escobar-Alvarez, S.; Goldgur, Y.; Yang, G.; Ouerfelli, O.; Li, Y.; Scheinberg, D. A. *J. Mol. Biol.* **2009**, *5*, 1211.
13. Antczak, C.; Shum, D.; Escobar, S.; Bassit, B.; Kim, E.; Seshan, V. E.; Wu, N.; Yang, G.; Ouerfelli, O.; Li, Y. M.; Scheinberg, D. A.; Djaballah, H. *J. Biomol. Screen* **2007**, *12*, 521.
14. Atkinson, R.; Mare, P.; Larsen, D. *J. Chem. Soc., Perkin Trans 2* **1983**, 271.
15. Singh, V.; Sapehiyia, V.; Kad, G. *ChemInform* **2003**, 34.
16. Lopez-Alvarado, P.; Avendano, C.; Menendez, J. *ChemInform* **2003**, 34.
17. Barrero, A.; Alvarez-Manzaneda, E.; Chahboun, R.; Diaz, C. *Synlett* **2000**, 1561.
18. Lin, Y.; Lang, S., Jr. *J. Org. Chem.* **1980**, *45*, 4857.
19. Cheng, J. International patent WO/2005/011670.
20. Cheng, X.; Liu, X. *J. Comb. Chem.* **2007**, *9*, 906.
21. Al-Mousawi, S.; Mohammed Abdel-Khalik, M.; El-Sherbiny, S.; John, E.; Elnagdi, M. *J. Heterocycl. Chem.* **2001**, *38*, 949.
22. Grinev, A.; Khun'Shchi-tszyun', A.; Terent'ev, A. *J. Gen. Chem. USSR* **1962**, *32*, 1931.
23. Grinev, A.; Arkhangel'skaya, N.; Uretskaya, G.; Vlasova, T. *Chem. Heterocycl. Compd.* **1975**, *11*, 639.
24. Nguyen, K.; Hu, X.; Colton, C. *Biochemistry* **2003**, *42*, 9952.
25. Shum, D.; Radu, C.; Kim, E.; Cajuste, M.; Shao, Y.; Seshan, V. E.; Djaballah, H. *J. Enzyme Inhib. Med. Chem.* **2008**, *23*, 931.